BTN3A1-BTN2A1 Binding Modulator for Vγ9Vδ2 T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecules that bind to butyrophilin 3A1 (BTN3A1) do not effectively promote the binding of BTN3A1 and BTN2A1, leading to insufficient activation of Vγ9Vδ2 T cells, and have poor drugability and in vivo activity.
Innovation Solution
Development of a small molecule compound that promotes the binding of the intracellular B30.2 domains of BTN3A1 and BTN2A1, enhancing the activation of Vγ9Vδ2 T cells and improving drugability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules bind to BTN3A1 alone, then they can interact with the target protein, but they fail to promote binding of BTN3A1 and BTN2A1 and cannot activate Vγ9Vδ2 T cells
Solution Approach 1:
The small molecule acts as an intermediary that simultaneously binds to both BTN3A1 and BTN2A1, facilitating their heteropolymer formation. The molecule bridges the two proteins through its dual binding capability, enabling the BTN3A1-BTN2A1 interaction that leads to Vγ9Vδ2 T cell activation.
Solution Approach 2:
The invention combines multiple binding functions into a single small molecule entity. The molecule is designed to interact with both BTN3A1 and BTN2A1 simultaneously, merging the binding activities toward both proteins into one compound that can promote heteropolymer formation and trigger immune cell activation.
2Reliability
If HMBPP is used to activate BTN3A1-BTN2A1, then high activation activity is achieved, but plasma stability is poor and drugability is difficult
Solution Approach 1:
The invention modifies the chemical parameters of HMBPP by replacing the labile isoprenoid side chain with a more stable aromatic or heteroaromatic group. This parameter change maintains the core binding activity while dramatically improving plasma stability and metabolic resistance, enabling the molecule to function as a viable drug candidate.
Solution Approach 2:
The patent creates a stable analog that replaces the short-lived, metabolically unstable HMBPP with a more durable molecular structure. The aromatic-based compound serves as a long-lasting alternative that resists degradation in plasma, effectively replacing the transient natural molecule with a persistent pharmacological agent.
3Reliability
If C-HMBPP is used instead of HMBPP, then some improvement in activity is achieved, but short-term stimulation activity remains weak
Solution Approach 1:
The invention optimizes the chemical parameters by introducing aromatic rings and heteroaromatic groups with specific electronic properties that enhance binding affinity and activation potency. These parameter adjustments result in compounds that exhibit superior short-term stimulation activity compared to both HMBPP and C-HMBPP.
4Ease of manufacture
If small molecules are designed for drugability, then pharmacological properties improve, but in vivo activity and clinical information remain undisclosed
Solution Approach 1:
The small molecules are designed with multi-functionality, combining pharmacological properties suitable for drug development with potent in vivo activity. The compounds exhibit both good drugability characteristics and demonstrated efficacy in animal models of cancer and infectious diseases, bridging the gap between pharmaceutical potential and proven therapeutic effect.
Data Source
Figure 1
Figure 2
AI summary
A compound of formula (I) or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, which can promote binding of butyrophilin 3A1/2A1, wherein the definitions of groups are as detailed in the description and the claims. Also involved are a pharmaceutical composition containing the compound of formula (I) and use thereof in clinical treatment.